Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/46184
Title: The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors
Authors: Vermersch, Patrick
Airas, Laura
Berger, Thomas
Deisenhammer, Florian
Grigoriadis, Nikolaos
Hartung, Hans-Peter
Magyari, Melinda
POPESCU, Veronica 
Pozzilli, Carlo
Pugliatti, Maura
Zakaria, Magd
VAN WIJMEERSCH, Bart 
Oreja-Guevara, Celia
Issue Date: 2025
Publisher: FRONTIERS MEDIA SA
Source: Frontiers in Immunology, 16 (Art N° 1495529)
Abstract: Background Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS), characterized by inflammation and neurodegeneration. The pathophysiology of MS, especially its progressive forms, involves various cellular components, including microglia, the primary resident immune cells of the CNS. This review discusses the role of microglia in neuroinflammation, tissue repair, and neural homeostasis, as well as their involvement in MS and explores potential therapeutic strategies targeting microglial function.Methods A literature search conducted in August 2023 and updated in March 2025, using the PubMed database, focused on articles relating to microglia and MS published in 2018-2025. Additionally, ongoing clinical trials of Bruton's tyrosine kinase (BTK) inhibitors were identified through the ClinicalTrials.gov website in November 2023 and updated in March 2025.Results Microglia are highly adaptive and exhibit various functional states throughout different life stages and play critical roles in neuroinflammation, tissue repair, and neural homeostasis. Their altered activity is a prominent feature of MS, contributing to its pathogenesis. Imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) provide insights into microglial activity in MS. BTK inhibitors and other novel treatments for MS, including masitinib and frexalimab, show promise in modulating microglial function and influencing the disease progression rate.Conclusions The multifaceted roles of microglia in CNS development, immune surveillance, and particularly in the pathogenesis of MS highlight the potential of targeting microglial functions in MS treatment. Emerging research on the involvement of microglia in MS pathophysiology offers promising avenues for developing novel therapies, especially for progressive MS, potentially improving patient outcomes in this debilitating disease.
Notes: Oreja-Guevara, C (corresponding author), Hosp Clin San Carlos, Dept Neurol, IdiSSC, Madrid, Spain.; Oreja-Guevara, C (corresponding author), UCM, Fac Med, Dept Med, Madrid, Spain.
orejacbn@gmail.com
Keywords: central nervous system;disease management;microglia;multiple sclerosis;neuroinflammation
Document URI: http://hdl.handle.net/1942/46184
ISSN: 1664-3224
e-ISSN: 1664-3224
DOI: 10.3389/fimmu.2025.1495529
ISI #: 001497640200001
Rights: 2025 Vermersch, Airas, Berger, Deisenhammer, Grigoriadis, Hartung, Magyari, Popescu, Pozzilli, Pugliatti, Van Wijmeersch, Zakaria and Oreja-Guevara. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
fimmu-1-1495529.pdfPublished version2.09 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.